Subject: "glucagon-like peptides" / Publication Year: 2012 / Subject: noninsulin-dependent diabetes mellitus / Text Availability: Citation in PubAg

Author:: Li, Pei-Bo; Lin, Wan-Ling; Wang, Yong-Gang; Peng, Wei; Cai, Xue-Ying; Su, Wei-Wei
Source:: International journal of biological macromolecules 2012 v.51 no.5 pp. 749-755
ISSN:: 0141-8130
Subject:: glucagon-like peptide 1, etc ; animal disease models; blood glucose; body weight; enzyme activity; excretion; fasting; glucagon; glucose tolerance; glycemic effect; glycogen; high fat diet; histopathology; kidneys; liver; noninsulin-dependent diabetes mellitus; oligosaccharides; oral administration; pancreas; rats; skeletal muscle; streptozotocin; Show all 22 Subjects
Abstract:: ... The aim of the present study is to investigate the antidiabetic properties of oligosaccharides of Ophiopogonis japonicus (OOJ) in experimental type 2 diabetic rats. OOJ was administered orally in doses of 225 and 450mg/kg body weight to high-fat diet and low-dose streptozotocin (STZ)-induced type 2 diabetic rats for 3 weeks. The results showed that OOJ treatment could increase body weight, decreas ...
DOI:: 10.1016/j.ijbiomac.2012.07.007
: http://dx.doi.org/10.1016/j.ijbiomac.2012.07.007

Author:: Guan, Ni; Gao, Weiwei; He, Min; Zheng, Min; Xu, Xiao; Wang, Xiaobo; Wang, Ming-Wei
Source:: Analytical biochemistry 2012 v.423 no.1 pp. 61-69
ISSN:: 0003-2697
Subject:: glucagon-like peptide 1, etc ; diagnostic techniques; islets of Langerhans; monitoring; cytotoxicity; free fatty acids; hydrogen peroxide; physiology; cytokines; toxic substances; bioassays; streptozotocin; noninsulin-dependent diabetes mellitus; Show all 13 Subjects
Abstract:: ... β-Cell injury plays an important role in the development of type 1 and type 2 diabetes. Most of the β-cell bioassays depend on labeling or endpoint assessments that might not capture the true physiology or pathology of the injury process. In the current study, we dynamically detected a broad range of pathological and pharmacological responses to four toxicants (cytokine mixture, free fatty acid mi ...
DOI:: 10.1016/j.ab.2012.01.014
: http://dx.doi.org/10.1016/j.ab.2012.01.014

Author:: Wei, Qian; Sun, Yu Qiang; Zhang, Jin
Source:: Peptides 2012 v.37 no.1 pp. 18-24
ISSN:: 0196-9781
Subject:: glucagon-like peptide 1, etc ; agonists; apoptosis; cell viability; fatty acids; insulin secretion; islets of Langerhans; lipotoxicity; mice; noninsulin-dependent diabetes mellitus; phosphatidylinositol 3-kinase; Show all 11 Subjects
Abstract:: ... Lipotoxicity plays an important role in the underlying mechanism of type 2 diabetes mellitus. Prolonged exposure of pancreatic β-cells to elevated concentrations of fatty acid is associated with β-cell apoptosis. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists have been reported to have direct beneficial effects on β-cells, such as anti-apoptotic effects, increased β-cell mass, and imp ...
DOI:: 10.1016/j.peptides.2012.06.018
: http://dx.doi.org/10.1016/j.peptides.2012.06.018

Author:: Triplitt, Curtis L.
Source:: TheDiabetes educator 2012 v.38 no.4_suppl pp. 23S-30S
ISSN:: 1554-6063
Subject:: glucagon-like peptide 1, etc ; adverse effects; agonists; comorbidity; diabetic complications; elderly; glycemic control; hyperglycemia; hypoglycemia; insulin; longevity; noninsulin-dependent diabetes mellitus; patients; renal failure; risk reduction; weight loss; Show all 16 Subjects
Abstract:: ... The purpose of this article is to review clinical issues related to the management of hyperglycemia in older patients with diabetes of long duration. Older adults represent an extensive proportion of patients with type 2 diabetes. Treatment goals need to be individualized to take into account comorbid conditions, life expectancy, diabetes complications, and the benefits of glycemic control. For bo ...
DOI:: 10.1177/0145721712449390
: http://dx.doi.org/10.1177/0145721712449390

Author:: Peters, Anne
Source:: TheDiabetes educator 2012 v.38 no.4_suppl pp. 13S-21S
ISSN:: 1554-6063
Subject:: glucagon-like peptide 1, etc ; agonists; comorbidity; glucose; glycemic control; hyperlipidemia; hypertension; noninsulin-dependent diabetes mellitus; obesity; patients; therapeutics; weight loss; Show all 12 Subjects
Abstract:: ... The purpose of this article is to review the treatment of a patient with type 2 diabetes who is commonly seen in practice—specifically, a middle-aged obese patient with micro- and macrovascular complications whose A1C rises after therapeutic intervention. Discussion of glucose management, as well as hypertension, dyslipidemia, and obesity comorbidities, is included. The key to successful treatment ...
DOI:: 10.1177/0145721712450620
: http://dx.doi.org/10.1177/0145721712450620

Author:: Cheong, Ye-Hwang; Kim, Mi-Kyung; Son, Moon-Ho; Kaang, Bong-Kiun
Source:: Biochemical and biophysical research communications 2012 v.417 no.1 pp. 558-563
ISSN:: 0006-291X
Subject:: glucagon-like peptide 1, etc ; agonists; antagonists; binding sites; calcium; mechanism of action; noninsulin-dependent diabetes mellitus; receptors; therapeutics; Show all 9 Subjects
Abstract:: ... The glucagon-like peptide-1 receptor (GLP-1R) is a target for type 2 diabetes treatment. Due to the inconvenience of peptide therapeutics, small-molecule GLP-1R agonists have been studied. Compound 2 (6,7-dichloro-2-methylsulfonyl-2-N-tert-butylaminoquinoxaline) and compound B (4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine) have been described as small molecule, ago-allos ...
DOI:: 10.1016/j.bbrc.2011.12.004
: http://dx.doi.org/10.1016/j.bbrc.2011.12.004

Main content area